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Regulation of Posttranslational Modifications
of HMGB1 During Immune Responses
Yiting Tang,1–3,* Xin Zhao,1,2,* Daniel Antoine,4 Xianzhong Xiao,5,6 Haichao Wang,7
Ulf Andersson,8 Timothy R. Billiar,9 Kevin J. Tracey,10 and Ben Lu1,2,5,10

Abstract

Significance: High-mobility group protein 1 (HMGB1) is an evolutionarily conserved and multifunctional
protein. The biological function of HMGB1 depends on its cellular locations, binding partners, and redox states.
Extracellular HMGB1 is a mediator of inflammation during infection or tissue injury. Immune cells actively
release HMGB1 in response to infection, which in turn orchestrates both innate and adaptive immune responses.
Recent Advances: Hyperacetylation of HMGB1 within its nuclear localization sequences mobilizes HMGB1
from the nucleus to the cytoplasm and subsequently promotes HMGB1 release. The redox states of the cysteines
in positions 23, 45, and 106 determine the biological activity of the extracellular HMGB1. Critical Issues: The
full picture and the detailed molecular mechanisms of how cells regulate the posttranslational modifications and
the redox status of HMGB1 during immune responses or under stress not only unravel the molecular mechanisms by which cells regulate the release and the biological function of HMGB1 but may also provide novel
therapeutic targets to treat inflammatory diseases. Future Directions: It is important to identify the signaling
pathways that regulate the posttranslational modifications and the redox status of HMGB1 and find their roles in
host immune responses and pathogenesis of diseases. Antioxid. Redox Signal. 24, 620–634.
Introduction

H

igh-mobility group protein 1 (HMGB1) is a 25-kDa
protein ubiquitously expressed and evolutionarily highly
conserved. HMGB1 is abundantly expressed in most kinds of
mammalian cells. The amino sequence of HMGB1 is 98.5%
identical in mammals (1). HMGB1 was first identified, 40
years ago, as a nonhistone chromatin-binding protein with
high electrophoretic mobility (1, 33). The major structural
features of HMGB1 are the two DNA-binding domains,
termed box A and box B, and a negatively charged C-terminal
acidic region. HMGB1 contains two nuclear localization se-

quences (NLS), which are recognized by the nuclear import
complexes, resulting in a predominantly nuclear localization
of HMGB1 under physiological conditions (1). Early studies
demonstrated that nuclear HMGB1 stabilizes chromatin
structure, modulates gene transcription, and promotes DNA
damage repair by bending the DNA helical structure (6a, 33).
Another early study showed that the cytoplasm also contains considerable amounts of HMGB1, implicating a role of
HMGB1 in the cytoplasm (36). Recently, Tang et al showed
that cytoplasmic HMGB1 can bind Beclin-1 and promote
mitophagy/autophagy and is thus involved in cell stress responses (77). Cell stress or infectious agents may stimulate
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HMGB1 translocation from the nucleus to the cytoplasm and
subsequent release into the extracellular milieu (1, 76).
Numerous studies have focused on the biological role of
extracellular HMGB1, since the protein is here involved in
a variety of immune responses, acting as a prototypic
damage-associated molecular pattern molecule (1). Extracellular HMGB1 was first identified as a late mediator of
endotoxemia and sepsis. Unlike most classical cytokines
that are released early during systemic inflammatory responses, HMGB1 is secreted in a delayed manner and
maintains high levels in the circulation after the onset of
sepsis (up to 100 ng/ml) (5, 85). Extracellular HMGB1
orchestrates the immune responses in a number of ways
(1, 83, 90). For example, HMGB1 may act as a proinflammatory mediator that stimulates tumor necrosis factor
(TNF) release during infection or sterile tissue injury
(72, 91). HMGB1 may also promote migration of monocytes, dendritic cells, and neutrophils (15, 63, 83). The
biological functions of extracellular HMGB1 are determined by its multiple reciprocal receptors, binding partners, and redox states (Fig. 1). In this context, fully reduced
HMGB1 (HMGB1C23hC45hC106h), with all three cysteines expressing thiol groups, forms a complex with stromal
cell-derived factor 1 (CXCL12) and synergistically promotes migration of immune cells via the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) and the
receptor for advanced glycation end products (RAGE);
partially oxidized HMGB1 with a disulfide bond between
cysteine 23 and cysteine 45, termed disulfide HMGB1
(HMGB1C23-C45C106h), triggers inflammatory responses
via Toll-like receptor (TLR) 4 (4, 82) but is unable to collaborate with CXCL12. The fully oxidized HMGB1, termed
sulfonyl HMGB1 (HMGB1C23soC45soC106so), has no
chemokine or cytokine activities. Intriguingly, HMGB1 may
form complexes with almost all kinds of nucleic acids, as
well as lipopolysaccharide (LPS), and increase the magnitude of immune responses to those agents (89, 94). In this
regard, HMGB1 was recently proposed as a promiscuous
receptor that broadly recognizes pathogen-derived molecules and amplifies immune responses initiated by pattern
recognition receptors, including TLR3, TLR4, TLR7, and
TLR9 (89) (Fig. 2).
HMGB1 is an important player in adaptive immune responses. Early works showed that HMGB1 induces the maturation of dendritic cells and promotes the proliferation of T
lymphocytes in an autocrine/paracrine manner (7, 14, 55).
Activated dendritic cells release HMGB1 a few hours before its
maturation. This process is critical for the efficient proliferation
of antigen-specific T lymphocytes and their polarization toward a T helper-1 phenotype (14, 55). In addition, dendritic
cell-released HMGB1 is important for the migration of dendritic cells to the draining lymph nodes, where dendritic cells
engage antigen-specific T lymphocytes (7). HMGB1 released
by dying tumor cells can also activate dendritic cells by
signaling through TLR4 and is critical for the dendritic cellmediated antitumor immunity during chemotherapy/radiotherapy (6). Notably, a TLR4 polymorphism that diminishes
the HMGB1 and TLR4 interaction predicts early relapse after
anthracycline-based chemotherapy in breast cancer patients
(6). Because the biological activity of HMGB1 is determined
by its redox status, it is not surprising that several environmental cues affect HMGB1-mediated immune responses. For
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example, reducing agents could prevent apoptosis-induced full
oxidation of HMGB1 and thus reverse the immunological
tolerance induction by apoptotic cells (41).
Although extracellular HMGB1 may play a crucial role in
mounting sufficient immune responses against invading
pathogens, excessive accumulation of HMGB1 in the circulation or the extracellular space in tissue deregulates homeostasis and may lead to diseases (1, 47). In addition to its
proinflammatory effects, extracellular HMGB1 prevents the
phagocytosis of Pseudomonas aeruginosa (16, 65). Accordingly, polyclonal or monoclonal antibodies that neutralize
the activity of HMGB1 significantly improve survival in
experimental sepsis and enhance bacterial clearance during
P. aeruginosa infection (1, 16, 65). Administration of antiHMGB1 antibodies or other HMGB1 antagonists, such as the
recombinant HMGB1 box A peptide, significantly ameliorates the severity of experimental rheumatoid arthritis, colitis, and pancreatitis and prevents cognitive decline after
experimental polymicrobial sepsis (1, 9, 38, 81). Importantly,
in vivo knockdown of HMGB1 expression by synthesized
short interfering RNAs (siRNA) in macrophages and dendritic cells dramatically reduced sepsis-induced mortality
(93). These observations establish that deregulated HMGB1
release drives the pathogenesis of a number of infectious and
autoimmune diseases, such as sepsis, rheumatoid arthritis,
and colitis. While it is obvious that HMGB1 can be passively
released from damaged or dying cells during tissue injury, it
is yet not fully understood how HMGB1 is discharged from
activated immune cells. This is a central question because the
identification of key pathways that regulate HMGB1 release
from activated immune cells may allow a design of novel
therapeutics to treat many inflammatory diseases. It is known
that posttranslational modifications of HMGB1 not only are
essential for HMGB1 release from activated immune cells
but also determine the biological activity of the released
HMGB1. In this review, we focus on the recently identified
signaling pathways controlling posttranslational modifications of HMGB1 and their roles in mediating HMGB1 release
in host immune responses and the pathogenesis of diseases.
Regulation of HMGB1 Release
from Activated Immune Cells

Most cytokines harbor a leader peptide that facilitates secretion through the endoplasmic reticulum (ER)—Golgi
exocytotic route. HMGB1, which lacks a leader peptide, is
released via unconventional protein secretion pathways (1,
49). Recent advance establishes two essential steps for
HMGB1 release from activated immune cells. In the first
step, infection or cellular stress induces the posttranslational
modification of HMGB1 that culminates in HMGB1 cytoplasmic accumulation. In the second step, pathogens and
endogenous danger signals induce rapid programmed cell
death that mediates cytoplasmic HMGB1 release into the
extracellular space or the formation of secretory lysosomes
that deliver HMGB1 outside cells (49) (Fig. 3).
Regulation of HMGB1 cytoplasmic accumulation
via posttranslational modifications of HMGB1
within the NLS sites

Protein shuttling between the nucleus and the cytoplasm
depends on NLS and nuclear export sequences (NES), which
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FIG. 1. The redox states of
the cysteines in positions 23, 45,
and 106 determine the biological activity of the extracellular
HMGB1. The fully reduced
HMGB1 forms a complex with
CXCL12 and synergistically
promotes migration of leukocytes via CXCR4 and RAGE;
partially oxidized HMGB1 with
a disulfide bond between cysteine 23 and cysteine 45 triggers
inflammatory responses and the
activation of leukocytes via
TLR4 but is unable to collaborate with CXCL12. The fully
oxidized HMGB1 has no chemokine or cytokine activities.
CXCL12, stromal cell-derived
factor 1; CXCR4, C-X-C chemokine receptor type 4;
HMGB1, high-mobility group
protein 1; RAGE, receptor for
advanced glycation end products; TLR, Toll-like receptor. To
see this illustration in color, the
reader is referred to the web
version of this article at www
.liebertpub.com/ars
are recognized by the nuclear import complex and nuclear
export complex, respectively (23). HMGB1 contains two
NLS sites and two nonclassical NES and therefore shuttles
continually between the nucleus and the cytoplasm. However, the equilibrium is almost completely shifted toward a
nuclear accumulation in most cells under physiological
conditions (8). It is well known that posttranslational modi-

fications of NLS or NES may block the interaction between
these proteins and nuclear import complex or nuclear export
complex and subsequently change the localization of intracellular proteins (23). These posttranslational modifications
include acetylation, phosphorylation, and methylation. Infection or cell stress can induce these modifications and shift
the equilibrium from a predominantly nuclear location

FIG. 2. The role of extracellular HMGB1 in PAMPinduced immune responses.
PRRs, such as TLR3, TLR4,
TLR7, TLR9, and RIG-1,
discriminatively sense distinct
PAMPs and initiate immune
responses, whereas extracellular HMGB1 promiscuously
binds multiple PAMPs and
broadly amplifies the PRRinduced immune responses.
PAMPs, pathogen associated
molecular patterns; PRRs,
pattern recognition receptors.
To see this illustration in
color, the reader is referred to
the web version of this article
at www.liebertpub.com/ars
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toward a cytoplasmic accumulation and a subsequent release
(8, 32, 95).
Acetylation is the most studied posttranslational modification that regulates HMGB1 cytoplasmic accumulation. The
two NLS sites contain four and five lysines, respectively (8,
17). Acetylation of these lysines is determined by both histone acetylases (HATs) and histone deacetylases (HDACs).
HDACs are a family of enzymes that remove acetyl groups
and control the acetylation state of histones and additional
intracellular proteins. HATs induce HMGB1 acetylation,
whereas the activity of HDACs is conversely correlated with
the extent of HMGB1 acetylation (8, 17). Bonaldi et al. first
described that stimulation of LPS, TNF, or IL-1b uniformly
induces HMGB1 hyperacetylation within NLS sites in
monocytes (8). This study provided three strong pieces of
evidence that HMGB1 hyperacetylation within NLS sites is
critical for HMGB1 translocation from the nucleus to the
cytoplasm as follows: (1) pharmacological inhibition of
HDACs that induces HMGB1 hyperacetylation translocates
HMGB1 from the nucleus to the cytoplasm; (2) mutation of
six lysines to glutamine, which mimics acetylated lysines,
also causes HMGB1 translocation from the nucleus to the
cytoplasm; and (6a) mutation of the same six lysines to arginine, which cannot be acetylated, blocks HMGB1 translocation from the nucleus to the cytoplasm in response to
HDAC inhibitors (8).
It should be noted that the ability to acetylate HMGB1 and
mobilize it from the nucleus to the cytoplasm is not the
privilege of immune cells only. Evankovich et al. demonstrated that liver ischemia/reperfusion (I/R) injury induces
HMGB1 acetylation and cytoplasmic accumulation in an
HDAC-dependent manner (17). During hypoxia, the levels of
acetylated HMGB1 significantly increased with a concomitant decrease in total nuclear HDAC activity in hepatocytes
(17). Among the HDAC family members, HDAC1 is a critical regulator of HMGB1 acetylation and translocation from
the nucleus to the cytoplasm during oxidative stress. Oxidative stress increases the expression of HDAC1 in hepatocytes.
Knockdown of HDAC1 by siRNA promoted HMGB1 cytoplasmic accumulation (17). Unlike immune cells, which actively release HMGB1 to modulate immune responses,
hepatocytes mobilize HMGB1 from the nucleus to the cytoplasm for a different reason. Cytoplasmic HMGB1 binds
Beclin-1 and promotes mitophagy/autophagy, self-protective
processes that remove damaged and reactive oxygen species
(ROS)-producing mitochondria (36, 37, 77). Accordingly,
hepatocyte-specific HMGB1 knockout mice have significantly increased liver injury compared to control mice in
response to I/R injury. The loss of intracellular HMGB1 in
the hepatocytes exacerbates mitochondrial damage and ROS
production (29). Interestingly, the oxidative stress, in return,
could enhance HMGB1 translocation from the nucleus to the
cytoplasm and release, possibly through the keap1/Nrf2
pathway, which is redox regulated and plays a key role in
protecting cells against redox stress (21, 44, 78). Due to the
oxidative stress, circulating HMGB1 released by damaged
or necrotic hepatocytes during liver injury carries the signature of the posttranslational modifications (5, 20). There
are several types of serum HMGB1 isoforms, including
disulfide-bonded hyperacetylated HMGB1, disulfide-bonded
nonacetylated HMGB1, and HMGB1 phosphorylated in
serine 35, in liver diseases, such as alcoholic liver disease and
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drug-induced liver injury (5, 20). Notably, increased total and
acetylated HMGB1 in serum were associated with worse
prognosis in patients with liver diseases. Acetylated HMGB1
was a better predictor of outcome than the total HMGB1 (5).
Regulation of HMGB1 cytoplasmic accumulation by JAK/
STAT1 pathway. We and others have previously estab-

lished an important role of type 1 and type 2 interferons (IFN)
and downstream janus kinase/signal transducers and activators of transcription ( JAK/STAT1) signaling activation in
mediating HMGB1 release (43, 69). In the light of these
findings, we recently explored the role of JAK/STAT1 signaling in regulation of HMGB1 nuclear translocation to the
cytoplasm. Indeed, pharmacological inhibition of JAK/
STAT pathways or genetic deletion of STAT1 blocks LPS- or
type 1 IFN-induced HMGB1 cytoplasmic accumulation (49).
The regulation of HMGB1 subcellular location by the JAK/
STAT1 is specific to LPS or IFN because pharmacological
inhibition of JAK/STAT does not affect rapamycin or hydrogen peroxide-induced HMGB1 cytoplasmic accumulation
(49). Mechanistically, JAK/STAT1 signaling is required for
LPS- or IFN-induced hyperacetylation of HMGB1 within the
NLS sites (49). In contrast, JAK/STAT1 signaling is dispensable for LPS- or IFN-induced HMGB1 intramolecular
disulfide bond formation, a posttranslational modification
that enables HMGB1 to initiate inflammatory responses by
signaling through TLR4 and myeloid differentiation factor 2
(MD2) (49). These observations pinpoint an important role of
the JAK/STAT1 in promoting HMGB1 acetylation and
subsequent cytoplasmic accumulation. The JAK/STAT1
signaling is the common downstream pathway of type 1 and
type 2 IFN (49). It is well known that type 1 and type 2 IFN
are cytokines that confer protection against intracellular
pathogens, such as virus and intracellular bacteria (62). These
facts raise an intriguing possibility that HMGB1 cytoplasmic
accumulation may be a host strategy to combat viral or intracellular bacterial invasion. This has elegantly been demonstrated by Taniguchi and colleagues to be the case
(89).Cytoplasmic HMGB1 augments foreign nucleic acidinduced innate immune responses, which are essential for
pathogen clearance (89). HMGB1 cytoplasmic accumulation
also promotes autophagy, which is a well-known cellular
strategy to remove intracellular bacteria and certain viruses.
However, this seemly protective response may under certain
conditions also be involved in the pathogenic pathways,
leading to sepsis. Several studies demonstrate that pharmacological inhibition of the JAK/STAT1 pathway or genetic
deletion of STAT1 significantly promotes survival in lethal
endotoxemia as well as experimental sepsis. These observations suggest that the JAK/STAT1 pathway may provide a
novel therapeutic target in sepsis (25, 43, 71).
The downstream mechanism by which JAK/STAT1 mediates HMGB1 acetylation is not fully understood. A recent
study reveals an important role of interferon response factor
(IRF) 1 for mediating HMGB1 acetylation during liver I/R
injury (13). Hypoxia induces the nuclear upregulation of
IRF1 in hepatocytes in a TLR4-dependent manner. Loss of
IRF1 in hepatocytes significantly inhibits HMGB1 acetylation and release (13). Mechanistically, IRF1-mediated
HMGB1 acetylation depends on the activity of histone
acetyltransferase. Liver I/R induces the physical interaction
between IRF1 and the nuclear histone acetyltransferase
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enzyme p300 (13). Notably, IRF1 is a downstream factor of
the JAK/STAT1 signaling in macrophages (61). Stimulation
of type 1 IFN significantly enhances IRF1 expression. Genetic deletion of IRF1 markedly reduces LPS-induced
HMGB1 release in macrophages and significantly promotes
survival during experimental sepsis (64). Thus, it is conceivable that IRF1 is one of the downstream factors of the
JAK/STAT1 signaling that mediates HMGB1 acetylation
and release in macrophages.
Regulation of HMGB1 cytoplasmic accumulation via
phosphorylation or methylation of HMGB1 NLS sites.

Acetylation is not the only type of posttranslational modification that regulates HMGB1 subcellular localization. Recent studies reveal that phosphorylation and methylation of
HMGB1 within the NLS sites also importantly regulate the
subcellular localization of HMGB1. Phosphorylation of
several plant HMG family proteins has been observed and
reported to modulate the interaction between these proteins
and DNA molecules. In the light of these studies, Youn et al.
found that stimulation of TNF or okadaic acid, a phosphatase
inhibitor, induces HMGB1 phosphorylation (95). The important role of phosphorylation in regulating HMGB1 subcellular localization was demonstrated by a nuclear import
assay, which showed that phosphorylated HMGB1 in the
cytoplasm did not enter the nucleus (95). There are six serine
residues within the two NLS sites. Substitution of these serine
residues to glutamic acid, that mimics the phosphorylated
serine, results in constitutively HMGB1 cytoplasmic accumulation. In contrast, replacement of these serine residues
with alanine inhibits okadaic acid-induced HMGB1 cytoplasmic accumulation (95). Positively charged residues are
abundant in the NLS and are necessary for binding to the
nuclear importin proteins, such as the karyopherins (11).
Thus, the underlying mechanism by which phosphorylation
of HMGB1 within NLS sites relocates HMGB1 into the cytoplasm might be that the phosphorylation alters the charge of
HMGB1 NLS sites and subsequently disrupts the interaction
between HMGB1 and the nuclear importin. The upstream
signaling pathway that regulates HMGB1 phosphorylation
within NLS sites is not fully understood. A recent study revealed an important role of calcium/calmodulin-dependent
protein kinase (CaMK) IV in the phosphorylation and release
of HMGB1 from LPS-stimulated macrophages (97). CaMK
IV-deficient macrophages display significantly decreased
HMGB1 serine phosphorylation and release in response to
LPS stimulation compared to the wild-type macrophages
(97). CaMK IV also regulates HMGB1 phosphorylation and
release in hepatocytes during I/R injury (80). However,
whether CaMK IV directly mediates HMGB1 serine phosphorylation within NLS sites remains to be elucidated.
During infection or autoimmune reactions, neutrophils are
an important source of extracellular HMGB1 (1). Unlike
other types of immune cells, most HMGB1 locates in the
cytoplasm rather in the nucleus (32). One explanation is that
HMGB1 in neutrophil is monomethylated at lysine 42. The
methylation at this site changes the conformation of HMGB1
and weakens its DNA-binding activity, causing it to accumulate in the cytoplasm by passive diffusion out of the nucleus (32). Thus, different types of cells might use distinct
posttranslational modifications to regulate HMGB1 subcellular location.

TANG ET AL.
Regulation of HMGB1 release
into the extracellular space

As mentioned above, HMGB1 lacks a leader peptide and
thus cannot be secreted by the conventional ER—Golgi
exocytotic route (1). Many studies have reported that
HMGB1 is actively released by immune cells during inflammation and proposed several separate pathways that
deliver HMGB1 from the cytoplasm to the extracellular
space. These unconventional protein secretion pathways include pyroptosis, necroptosis, apoptosis, NETosis, and secretory lysosome-mediated release.
HMGB1 release via pyroptosis. Despite the fact that
HMGB1 can be released into the extracellular space through
many different routes, a fundamental question in the field
remains to be answered: What is the dominant pathway that
mediates HMGB1 release in inflammatory diseases, such as
sepsis? An early study unexpectedly demonstrated that
pharmacological inhibition of caspase activity significantly
blocked HMGB1 release and promoted survival in experimental sepsis (68). The improved survival rate in the caspase
inhibitor-treated groups was, at least in part, due to a reduced
HMGB1 release since HMGB1-neutralizing monoclonal
antibodies dose dependently promoted survival in experimental sepsis (68). The pan-caspase inhibitor, used in this
study, inhibited both caspase-3-mediated apoptosis and
caspase-1/caspase-11-mediated pyroptosis, which is a
proinflammatory programmed cell death form (46). This
raises an intriguing question: Which is the dominant pathway
that mediates HMGB1 release during experimental sepsis:
apoptosis or caspase-1/caspase-11-mediated pyroptosis?
Most transgenic caspase-1 knockout mice also lack caspase11 and thus have a reduced capacity for the induction of
pyroptosis. Lamkanfi et al. found that these caspase-1/
caspase-11-double-deficient mice have markedly lower serum HMGB1 levels during lethal endotoxemia compared to
wild-type mice (46). This observation clearly indicates that
pyroptosis is the dominant pathway that mediates HMGB1
release during endotoxemia. Accordingly, caspase-1/
caspase-11-double-deficient mice have markedly higher
survival rate during lethal endotoxemia compared to their
wild-type controls (46). In addition to its role in pyroptosis,
caspase-1 is critical for the maturation of pro-IL-1b and proIL-18, both of which are well-established proinflammatory
cytokines. Surprisingly, genetic deletion of both IL-1b and
IL-18 did not confer any protection against lethal endotoxemia
(46). In contrast, HMGB1 neutralization via HMGB1-specific
antibodies significantly prevented endotoxemia-induced death
(46). These observations underscore the importance of the
interplay between caspase-1/caspase-11 and HMGB1 in the
pathogenesis of sepsis.
Caspase-1 and caspase-11 are activated by canonical and
noncanonical inflammasomes, respectively (39). The inflammasome is a key component for innate immune responses and a sentinel protein complex that surveys the
intracellular environment. The canonical inflammasome
consists of at least two distinct components, including
procaspase-1, and an NOD-like receptor (NLR) molecule or a
molecule of the pyrin and HIN-200 domain-containing
family. In response to certain danger signals, these proteins
assemble into functional inflammasome complexes and
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subsequently activate caspase-1, which in turn mediates the
maturation of pro-IL-1b and pro-IL-18, as well as pyroptosis
(74). Dixit and colleagues. recently discovered a noncanonical inflammasome, which activates caspase-11 rather
than caspase-1 (39). Caspase-11 physically interacts with
caspase-1, and contributes to the activation of caspase-1, upon
activation by noncanonical stimuli, such as Escherichia coli
bacteria (39, 86). Notably, caspase-11 may mediate pyroptosis
and HMGB1 release in the absence of caspase-1. Genetic deletion of caspase-11, rather than caspase-1, protects mice from
lethal endotoxemia (39). Recent studies reveal that intracellular LPS induces caspase-11 activation even in the absence of
its known receptor TLR4 (22, 40) (Fig. 4).
It is noteworthy that HMGB1 released via pyroptosis has
specific translational modifications. Mass spectrometry
analysis reveals that HMGB1 released via pyroptosis is hyperacetylated at the NLS sites, whereas HMGB1 released via
freeze–thaw cycle-induced necrosis contains hypoacetylated
NLS sites (27). Together with the finding that HMGB1 hyperacetylation at NLS sites is essential for HMGB1 translocation from the nucleus to the cytoplasm, which greatly
facilitates subsequent HMGB1 release, these observations
implicate that HMGB1 release upon inflammasome activation is a highly regulated process. Interestingly, different
types of inflammasome activation may induce distinct posttranslational modifications of HMGB1. In this context,
NLRP3 inflammasome stimuli, including adenosine triphosphate (ATP), monosodium uric acid (MSU), and adjuvant aluminum, induce HMGB1 disulfide bond formation
between cysteine 23 and cysteine 45 (27). In contrast, activation of the NLRC4 inflammasome results in the release of
the fully reduced all-thiol form of HMGB1 (35). One possible
explanation for these phenomena is that the activation of the
NLRP3 inflammasome, but not the NLRC4 inflammasome, is
associated with mitochondrial ROS production, which may
oxidize HMGB1 and induce the Cys23–Cys45 disulfide bond
formation (98). Both the NLRP3 and the NLRC4 inflammasome mediate the maturation of IL-1b and IL-18.
However, the distinct redox states of HMGB1 may fine-tune
the immune responses against different invading pathogens.
For example, the NLRP3 inflammasome can be activated by
several types of RNA viruses (45), which can generate extracellular HMGB1 with a disulfide bond that can activate
TLR4 cascades to initiate inflammation and IFN production
(1) that will augment the antiviral immune responses (89).
The NLRC4 inflammasome is an intracellular sentinel
against Salmonella typhimurium infection (56). The recruitment of neutrophils is essential for clearance of S. typhimurium (56). Accordingly, the fully reduced HMGB1, whose
release is mediated by the NLRC4 inflammasome, will
markedly increase the migration of neutrophils by forming
protein complexes with CXCL12 to signal through the
CXCR4 receptor (63, 82).
HMGB1 release via necroptosis. Necrotic cells passively
release HMGB1 and trigger sterile inflammation (63, 82).
Genetic deletion of HMGB1 or neutralization of extracellular
HMGB1 activity markedly reduces necrotic cell-induced
TNF production, establishing a critical role for HMGB1 in
sterile tissue injury (72, 91). It was previously thought that
necrosis is not a programmed cell death. However, recent
advances reveal that necrosis induced by cytokines (e.g.,
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TNF) or some viral infection may reflect a highly regulated
process termed necroptosis or programmed necrosis (10, 24).
The protein kinase receptor-interacting protein 3 (RIP3) is a
molecular switch between TNF-induced apoptosis and necrosis. In the presence of a pan-caspase inhibitor, TNF
stimulation results in the formation of an RIP3–RIP1 protein
complex, which executes the necrotic process (10, 24, 58). In
addition to TNF, type 1 or type 2 IFN can also induce necroptosis when the adaptor protein fas-associated death domain is lost or the caspase activity is blocked, which, for
example, may occur during energy deprivation. Stimulation
of IFN markedly induces the formation of RIP3–RIP1 complexes via the JAK/STAT1 pathway (79). It is clear that
mitochondria-derived ROS are involved in the necroptosis
process and partially account for the ability of RIP3–RIP1
protein complexes to promote the programmed necrosis (96).
Thus, it will be of great interest to investigate whether
HMGB1 released via necroptosis contains the Cys23–Cys45
disulfide bond or not.
Regulation of HMGB1 release by apoptosis. Unlike necrosis, apoptotic cells do not significantly release HMGB1 at
the early stage when HMGB1 is retained within the nucleus
surrounded by a cell membrane (72). Bacterial LPS or
polyinosinic–polycytidylic acid, a double-stranded RNA
(dsRNA) mimetic, could induce apoptosis of mouse macrophage. Using this in vitro system, Jiang et al. observed that
HMGB1 release is correlated with the percentage of cells
undergoing apoptosis (34). Indeed, apoptotic cells release
HMGB1 during the late stage of apoptosis, termed secondary
necrosis, which may occur if the removal and degradation of
apoptotic bodies are inadequate (81). In this context, HMGB1
remains bound to nucleosomes released at the late stage of
apoptosis. HMGB1-containing nucleosomes from apoptotic
cells could induce the production of proinflammatory cytokines, such as TNF and IL-1b, and the maturation of the
dendritic cells (81). Notably, HMGB1–nucleosome complexes can be detected in plasma from patients with systemic
lupus erythematosus (SLE) (81). Injection of HMGB1containing nucleosomes from apoptotic cells induced antidsDNA and antihistone IgG responses in a TLR2-dependent
manner in mice (81). These findings suggest that apoptotic
cell-released HMGB1-containing nucleosomes may crucially contribute to the pathogenesis of SLE. Interestingly,
apoptotic cells could stimulate macrophage to release
HMGB1. Administration of a pan-caspase inhibitor, which
blocks apoptosis, markedly reduced serum HMGB1 levels
during experimental sepsis (68). One possible underlying
mechanism is that apoptotic cells robustly secrete ATP,
which in turn activates the NLRP3 inflammasome in immune
cells, which subsequently results in HMGB1 release (79).
Accordingly, overexpression of the antiapoptotic gene, bcl-2
gene, or pharmacological inhibition of apoptosis markedly
reduces HMGB1 release and improves the survival in experimental sepsis (68). It is noteworthy that apoptotic cells
also release HMGB1-containing microparticles (66, 67).
Microparticles are small membrane-bound vesicles that are
released from cells during cell death or cell activation (67).
In vitro, bacterial LPS or polyinosinic–polycytidylic acid
could stimulate macrophage-like RAW 267.4 cells to secrete
HMGB1-containing microparticles, whose release is associated with apoptosis (66, 67). Growing evidence indicates that
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the microparticles exert proinflammatory and prothrombotic
effects. These studies also suggest that microparticles released during systemic inflammation are markers and mediators of microvascular dysfunction, immunosuppression, and
renal dysfunction and that HMGB1 might contribute to the
proinflammatory activity of the microparticles (66, 67, 73).
Regulation of HMGB1 release by double-stranded RNAdependent kinase (PKR). PKR is a 65-kDa intracellular

protein, which contains two RNA-binding domains at the Cterminal and a kinase domain at the N-terminal (12). Although PKR was originally identified as an intracellular
dsRNA receptor and a key antiviral protein, recent studies
implicate that it is also an intracellular stress-sensing molecule (88). In addition to dsRNA, bacterial components and
free fatty acid induce PKR autophosphorylation (28, 59). In
the light of these findings, we recently identified an important
role of PKR in inflammasome activation and HMGB1 release
(56). Genetic deletion or pharmacological inhibition of PKR
markedly reduces inflammasome activation induced by various NLRP3 agonists and the NLRP1 agonist, anthrax lethal
toxin (LTx) (56). Overexpression of PKR significantly enhances the activity of the reconstituted NLRP3 and NLRP1
inflammasomes in nonimmune cells. These findings clearly
indicate that PKR is an important regulator of several inflammasomes and subsequent HMGB1 release. However, the
mechanisms by which PKR regulates inflammasome activation remain unknown. It is unlikely that PKR regulates inflammasome activation through phosphorylation of its
substrates, partly because we did not find any phosphorylation
of the inflammasome components (56) and partly because a
mutant PKR that lost its kinase activity still activated the
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NLRP3 and NLRP1 inflammasomes (our unpublished data).
A recent study made similar observations to ours. Knockdown of PKR expression by siRNA in macrophages blocked
LTx-induced inflammasome activation and subsequent pyroptosis (26). Addition of a PKR inhibitor, 7-desacetoxy-6,7dehydrogedunin, significantly inhibited the NLRP3 and
NLRP1 inflammasome agonist-induced apoptosis-associated
speck-like protein containing a CARD oligomerization,
caspase-1 activation, and pyroptosis in macrophages (26).
Intriguingly, PKR also participates in other types of programmed cell death, including apoptosis and necroptosis (28,
79). Bacteria or their components, such as LPS, induced robust PKR phosphorylation and apoptosis in macrophages
(28). Genetic deletion of PKR dramatically inhibited
bacteria-induced macrophage apoptosis (28). The proapoptotic actions of PKR are, at least in part, mediated via
inhibition of protein synthesis and activation of IRF3 because
elF-2a or IRF3 deficiency significantly inhibited bacteriainduced apoptosis (28). A recent study showed that PKR is
also required for type 1 or type 2 IFN-induced necroptosis
(79). IFN transcriptionally activated PKR, which physically
interacted with RIP1 to facilitate RIP3–RIP1 protein complex
formation (79). Together with the identification of PKR as an
important regulator of inflammasome-mediated pyroptosis
(26, 56), these observations establish PKR as a master regulator of multiple programmed cell death pathways.
It is noteworthy that aforementioned facts provide novel
insights into the comprehensive role of PKR in antiviral responses (Fig. 5). Numerous types of viruses inhibit PKR
expression or activation, implicating important roles of PKR
in antiviral responses (57). In addition to dsRNA molecules
derived from RNA viruses, a variety of cellular stress

FIG. 3. The mechanisms
for HMGB1 release from
activated immune cells.
There are two steps for
HMGB1 release from activated immune cells. In the
first step, DAMPs or PAMPs
stimulate the posttranslational modifications (M) of
HMGB1 at the nuclear localization sequence sites in
immune cells. This leads to
the translocation of HMGB1
from the nucleus to the cytoplasm. In the second step, the
DAMPs or PAMPs induce
HMGB1 release into the extracellular space either through
the formation of secretory lysosomes or through the activation of cell death programs,
such as pyroptosis and necroptosis. DAMP, damageassociated molecular pattern
molecule. To see this illustration in color, the reader is referred to the web version of
this article at www.liebertpub
.com/ars
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FIG. 4. The activation of
caspase-11. Mouse caspase11 and human caspase-4/5 are
the receptors for intracellular
LPS. During Gram-negative
bacterial infection, the lysis of
bacteria-containing phagosomes results in LPS translocation to the cytoplasm. This
culminates in the LPS recognition by caspase-4/5/11, which
subsequently forms oligomers
and mediates pyroptosis that
leads to HMGB1 release. LPS,
lipopolysaccharide. To see this
illustration in color, the reader
is referred to the web version of
this article at www.liebertpub
.com/ars

FIG. 5. The role of PKR in
antiviral responses. dsRNA
molecules derived from RNA
viruses and different forms of
cellular stress can induce PKR
dimerization and autophosphorylation. PKR contributes
to the antiviral responses at
many levels: (1) It recruits and
phosphorylates eIF2a, resulting
in inhibition of viral protein
synthesis and apoptosis; (2)
PKR enhances type 1 IFN
production by interaction with
IRF3 and NF-kB pathways; (3)
PKR regulates actin dynamics
and abrogates viral entry into
cells by inhibiting gelsolin; and
(4) PKR physically interacts
with inflammasome components or RIP1 and promotes
pyroptosis and necroptosis.
dsRNA, double-stranded RNA;
IFN, interferons; IRF, interferon response factor; NF-kB,
nuclear factor-kappa B; RIP,
receptor-interacting protein. To
see this illustration in color, the
reader is referred to the web
version of this article at www
.liebertpub.com/ars
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FIG. 6. Activation of TLRmediated signaling may induce HMGB1 Cys23–Cys45
disulfide bond formation.
Activation of TLRs results in
the translocation of TRAF6 to
mitochondria, where it interacts with the protein ECSIT.
This is followed by ECSIT
ubiquitination and enrichment
in the mitochondria, culminating in significantly increased mitochondrial ROS
generation. It is conceivable that this TLR–TRAF6–
ECSIT–mitochondrial ROS
signal pathway promotes
HMGB1 oxidation during inflammation. ECSIT, evolutionarily conserved signaling
intermediate in Toll pathway;
ROS, reactive oxygen species;
TRAF6, tumor necrosis factor
receptor-associated factor 6.
To see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars

processes, such as ER stress, mitochondrial damage, metabolic stress, and cytotoxicity, also induce PKR activation (12,
28, 56, 59, 88). In this context, the intact dsRNA-binding
domain of PKR is required for PKR activation, implicating
the existence of endogenous dsRNA molecules generated
during cellular stress (59). Functioning as both a viral RNA
receptor and a cellular stress response molecule, PKR may
broadly detect all kinds of viral infections. Upon ligand
recognition, PKR uncovers its intramolecular dimerization
domain, culminating in PKR dimerization and its subsequent
autophosphorylation (12). Phosphorylated PKR contributes
to the antiviral responses in multiple ways as follows: (i) It
recruits and phosphorylates eIF2a, resulting in inhibition of
viral protein synthesis (12); (ii) PKR enhances type 1 IFN
production by the interaction with IRF3 and nuclear factorkappa B pathways (54, 88); (iii) PKR activation regulates
actin dynamics and abrogates viral entry into cells by inhibiting gelsolin, a key actin-modifying protein (31); and (iv)
PKR physically interacts with inflammasome components,
RIP1, or IRF3 and broadly promotes programmed cell death,
including apoptosis, pyroptosis, and necroptosis (26, 28, 56,
79). Apoptosis, pyroptosis, and necroptosis are important
strategies for the host to directly eliminate the intracellular
virus or in mounting sufficient antiviral immune responses
(57). However, deregulated PKR expression and phosphorylation might contribute to the pathogenesis of a number of
diseases (56). Studies show that PKR deficiency confers resistance to high-fat diet-induced obesity and insulin resistance, as well as Alzheimer’s disease, suggesting PKR as a
potential therapeutic target in these diseases (48, 59).
HMGB1 release via NETosis. NETosis is a type of programmed cell death in activated neutrophils. In response to

proinflammatory stimuli, such as LPS, TNF-a, and ROS,
neutrophils release its DNA and numerous DNA-binding
proteins, including HMGB1, into the extracellular milieu and
form the neutrophil extracellular traps (NETs) (75). NETs
play an important role in preventing microbial dissemination
and promoting bacterial clearance (75). However, deregulated NET formation could contribute to the tissue damage
and the pathogenesis of diseases, such as SLE and liver I/R
injury (18, 30). For example, abnormal NET formation exerts
a pathogenic role in SLE through the enhanced production of
type 1 IFN (66). NETs are an important source of extracellular HMGB1 in this context. HMGB1 could significantly
increase NET DNA-induced production of IFN-a and other
cytokines in a TLR9-dependent manner in immune cells (75).
Notably, HMGB1 could induce NET formation by signaling
through the TLR4 and TLR9 and thus further increase the
levels of extracellular HMGB1 (18, 30).
HMGB1 release via secretory lysosome. Activated immune cells release HMGB1 through two routes as follows:
programmed cell death and exocytosis of secretory lysosome
(50). Previous studies demonstrated that some leaderless
proteins that cannot be secreted by the ER—Golgi exocytotic
pathway—can be released into the extracellular space by the
caspase-1-mediated unconventional protein secretion pathway (42). These proteins include caspase-1 and its binding
partners, such as IL-1a and fibroblast growth factor-2 (42).
Rubartelli and colleagues found that caspase-1 and its substrate IL-1b are packed into vesicle compartments, termed
secretory lysosomes, before their release from activated
monocytes (2). Unlike the conventional lysosomes, secretory
lysosomes are specialized organelles that deliver their cargo
into the extracellular space via exocytosis (2). Notably,
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cytoplasmic HMGB1 is also located in secretory lysosomes
after LPS stimulation in human monocytes (19). Although
both IL-1b and HMGB1 are released by secretory lysosomes,
the upstream signals that trigger IL-1b or HMGB1 release are
different. IL-1b secretion is induced earlier by ATP stimulation, which is followed by potassium efflux, whereas
HMGB1 secretion is triggered by lysophosphatidylcholine
(19). These observations provide evidence for those live
immune cells that may actively release HMGB1 upon stimulation in addition to the already discussed pyroptotic or
necroptotic pathways in dying cells. However, the intracellular signal pathways that control the formation of secretory
lysosomes and the sequestration of cytoplasmic HMGB1 in
secretory lysosomes remain largely unknown.
HMGB1 release during platelet activation. Early observations identified HMGB1 as an endogenous protein in platelets, which export HMGB1 from the intracellular compartment
to the cell surface upon platelet activation (70). Maugeri et al.
showed that platelets are an important source of the extracellular HMGB1 during vascular injury and that platelet-derived
HMGB1 mediates platelet-induced neutrophil activation and
NET formation by signaling through the RAGE (51, 53). In
addition, platelet-derived HMGB1 promotes neutrophil survival, possibly through induction of autophagy and prevention
of mitochondrial damage in neutrophils (53). Interestingly, the
ROS generated by the activated neutrophils could enhance the
proinflammatory activity of HMGB1 during vascular injury
(53). Thus, the platelet-derived HMGB1 and the activated
neutrophils form a positive feedback loop that amplifies inflammatory responses during sterile injury. It is noteworthy
that decreased HMGB1 content and HMGB1 translocation to
the outer leaflet of the plasma membrane were observed in
circulating platelets of patients with systemic sclerosis compared to those of age-matched healthy controls, implying that
platelet-derived HMGB1 contributes to pathogenesis of the
disease (52). Recently, two studies independently showed that
HMGB1 released by activated platelets is critical for regulating
platelet activation, granule secretion, and adhesion by signaling through the TLR4 and guanylyl cyclase pathway (84, 92).
Together, these studies establish that the platelet-derived
HMGB1 is a critical player in both inflammation and thrombosis.
Regulation of HMGB1 Oxidation

HMGB1 contains three evolutionarily conserved cysteines
(Cys23, Cys45, and Cys106). The redox states of these cysteines determine the biological function of extracellular
HMGB1. Specifically, fully reduced HMGB1 forms a complex with CXCL12 and promotes the migration of immune
cells via CXCR4 and RAGE. Partially oxidized HMGB1 with
a disulfide bond between cysteine 23 and cysteine 45 initiates
inflammatory responses by signaling through TLR4 (4, 82).
The fully oxidized HMGB1, however, exerts neither chemotactic nor proinflammatory effect (41). While it is clear
that redox modifications of HMGB1 importantly shape the
innate immune responses, questions about how redox modifications of HMGB1 are regulated during immune responses
remain largely unanswered at present.
Under physiological conditions, the majority of intracellular HMGB1 is fully reduced (49). The evidence that redox
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modifications of HMGB1 during immune responses are
highly regulated processes comes from a study, which shows
that a caspase- and mitochondria-dependent pathway mediates a terminal oxidation of HMGB1 in cells undergoing
apoptosis (41). When the cellular apoptotic program is initiated, the activated caspases target mitochondria to produce
excessive ROS (41). This event culminates in a terminal
oxidation of HMGB1 expressing sulfonic groups, which
renders HMGB1 immunologically inactive (41). Accordingly, unlike necrosis, which often results in inflammation
and adaptive immune responses, apoptosis tends to be antiinflammatory and promotes immune tolerance (41). Importantly, blocking sites of oxidation by mutation of the
redox-sensitive cysteines in HMGB1 prevented immune
tolerance induced by apoptotic cells (41). In addition, apoptotic cell-induced immune tolerance could be blocked when
caspase-dependent ROS activity was blocked by scavenging
or mutation of a mitochondrial caspase target, p75 NDUSF1
(41). Together, these observations not only indicate that redox modifications of HMGB1 critically orchestrate immune
responses during sterile tissue injury but also clearly provide
evidence that mitochondrial ROS mediate HMGB1 oxidation.
Intriguingly, extracellular ATP- and MSU-induced pyroptosis, a proinflammatory mode of cell death that is initiated
by the activation of caspase-1 and involves robust mitochondrial ROS production (56), leads to the release of partially oxidized HMGB1 with a Cys23–Cys45 disulfide bond
and a reduced Cys106. Unlike apoptotic cells, which restrain
and condense intracellular proteins at the early stage of apoptosis, cells undergoing pyroptosis rapidly release their intracellular contents, including HMGB1 (39, 72, 74). This is
likely the reason why HMGB1 released by pyroptotic cells is
partially oxidized, while that released by apoptotic cells is
terminally oxidized. Applequist and colleagues showed that
the activation of caspase-1 does not mediate HMGB1 oxidation because the activation of the NLRC4 inflammasome
by intracellular flagellin failed to induce HMGB1 oxidation
(60). In contrast, we recently demonstrated that activation via
TLR4 signaling induces HMGB1 Cys23–Cys45 disulfide
bond formation (49). In line with this finding, a recent study
showed that activation of TLR1, TLR2, and TLR4 augments
mitochondrial ROS production (87). Mechanistically, activation of these TLRs results in the translocation of a TLR
signaling adaptor protein, tumor necrosis factor receptorassociated factor 6 (TRAF6), to the mitochondria, where it
interacts with the protein evolutionarily conserved signaling
intermediate in Toll pathways (ECSIT). This is followed by
ECSIT ubiquitination and enrichment in the mitochondria,
culminating in significantly increased mitochondrial ROS
generation (87). Thus, it is conceivable that this TLR–
TRAF6–ECSIT–mitochondrial ROS signal pathway mediates HMGB1 oxidation during inflammation (Fig. 6).
Conclusions and Perspectives

In summary, HMGB1 is a multifunctional protein, and its
biological activity and subcellular location are determined by
distinct posttranslational modifications. These posttranslational modifications of HMGB1 in serum or tissue samples
were analyzed by liquid chromatography–mass spectrometry
(5, 20). Characterization of whole protein molecular weights,
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acetylated lysine residues, or redox modifications on cysteine
residues within HMGB1 was performed by tandem mass
spectrometry (5, 20). The data discussed in this review have
identified some of the signaling pathways that control the
posttranslational modifications of HMGB1 and their roles in
mediating HMGB1 release in host immune responses and the
pathogenesis of diseases. In this context, JAK/STAT1 signaling promotes HMGB1 acetylation within the NLS sites,
leading to the translocation of HMGB1 from the nucleus to
the cytoplasm. The TLR–mitochondrial ROS pathway induces partial oxidation of HMGB1 and formation of a
Cys23–Cys45 disulfide bond, which enables HMGB1 to activate the TLR4–MD2 complex and initiate inflammation.
However, the molecular mechanisms of how cells regulate
the posttranslational modifications of HMGB1 during immune responses or under stress are not fully understood. For
example, certain stress influences may induce HMGB1 hyperacetylation in a JAK/STAT1-independent manner, which
emphasizes that additional yet unresolved signal pathways
regulate HMGB1 acetylation during stress responses. Another
puzzle in this field is how the JAK/STAT1 pathway regulates
HMGB1 acetylation, although it is likely that a downstream
factor is either an acetylase or a partner molecule of an acetylase. In addition to acetylation, phosphorylation and methylation of HMGB1 within the NLS sites have also been
demonstrated to promote HMGB1 translocation from the nucleus to the cytoplasm. How these separate posttranslational
modifications of HMGB1 work in concert to determine
HMGB1’s subcellular localization remains still unknown.
Finding the answers to these unresolved questions will not only
unravel the molecular mechanisms by which cells regulate the
posttranslational modifications of HMGB1 but may also provide novel therapeutic targets to treat inflammatory diseases.
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Abbreviations Used
ATP ¼ adenosine triphosphate
CaMK ¼ calcium/calmodulin-dependent
protein kinase
CARD ¼ caspase recruitment domain
CXCL12 ¼ stromal cell-derived factor 1
CXCR4 ¼ C-X-C chemokine receptor type 4
Cys ¼ cysteines
DAMP ¼ damage-associated molecular pattern
molecule
dsRNA ¼ double-stranded RNA
ECSIT ¼ evolutionarily conserved signaling
intermediate in Toll pathways
ER ¼ endoplasmic reticulum
HATs ¼ histone acetylases
HDACs ¼ histone deacetylases
HMGB1 ¼ high-mobility group protein 1
IFN ¼ interferons
IL-18 ¼ interleukin-18
IL-1b ¼ interleukin-1b
IRF ¼ interferon response factor
I/R ¼ ischemia/reperfusion
JAK/STAT1 ¼ janus kinase/signal transducers and
activators of transcription
LPS ¼ lipopolysaccharide
LTx ¼ anthrax lethal toxin
MD2 ¼ myeloid differentiation factor 2
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NF-kB
NLR
NLRC4
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¼

NLRP1
NLRP3
NLS
p75 NDUSF1
PAMPs
PKR
PRRs
RAGE
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¼

RIP1
RIP3
ROS
siRNA
SLE
TLR
TNF
TRAF6
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¼

monosodium urate monohydrate
nuclear export sequences
neutrophil extracellular traps
nuclear factor-kappa B
NOD-like receptor
the nucleotide-binding domain,
leucine-rich repeat containing
family caspase recruitment
domain-containing 4
NLR family pyrin domain-containing 1
NLR family pyrin domain-containing 3
nuclear localization sequences
NADH dehydrogenase Fe-S protein-1
pathogen associated molecular patterns
double-stranded RNA-dependent kinase
pattern recognition receptors
receptor for advanced glycation
end products
receptor-interacting protein 1
receptor-interacting protein 3
reactive oxygen species
synthesized short interfering RNAs
systemic lupus erythematosus
Toll-like receptor
tumor necrosis factor
tumor necrosis factor receptorassociated factor 6

